Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers

(marketscreener.com) Lonza to support the development and manufacturing of CTIM-76, Context’s CLDN6 x CD3 bispecific antibody clinical candidate The bispecific antibody-based therapy is being developed to redirect T-cell mediated lysis toward malignant cells expressing CLDN6 PHILADELPHIA and BASEL, Switzerland, Jan. 09, 2023 -- Context Therapeutics Inc. ,...https://www.marketscreener.com/quote/stock/CONTEXT-THERAPEUTICS-INC-125228671/news/Context-Therapeutics-and-Lonza-Enter-Manufacturing-Agreement-for-Bispecific-Antibody-Targeting-Claud-42691733/?utm_medium=RSS&utm_content=20230109